Cargando…

Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis

Gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) can detect early stages of hepatocellular carcinoma (HCC). However, the survival benefit of Gd-EOB-DTPA-enhanced MRI in the surveillance of patients with cirrhosis has not yet been determined. We explored whether the int...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Su Jong, Yoo, Jeong-Ju, Lee, Dong Ho, Kim, Su Jin, Cho, Eun Ju, Kim, Se Hyung, Lee, Jeong-Hoon, Kim, Yoon Jun, Lee, Jeong Min, Lee, Jae Young, Yoon, Jung-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953123/
https://www.ncbi.nlm.nih.gov/pubmed/36830919
http://dx.doi.org/10.3390/biomedicines11020382
_version_ 1784893799948877824
author Yu, Su Jong
Yoo, Jeong-Ju
Lee, Dong Ho
Kim, Su Jin
Cho, Eun Ju
Kim, Se Hyung
Lee, Jeong-Hoon
Kim, Yoon Jun
Lee, Jeong Min
Lee, Jae Young
Yoon, Jung-Hwan
author_facet Yu, Su Jong
Yoo, Jeong-Ju
Lee, Dong Ho
Kim, Su Jin
Cho, Eun Ju
Kim, Se Hyung
Lee, Jeong-Hoon
Kim, Yoon Jun
Lee, Jeong Min
Lee, Jae Young
Yoon, Jung-Hwan
author_sort Yu, Su Jong
collection PubMed
description Gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) can detect early stages of hepatocellular carcinoma (HCC). However, the survival benefit of Gd-EOB-DTPA-enhanced MRI in the surveillance of patients with cirrhosis has not yet been determined. We explored whether the intermittent replacement of ultrasonography (USG) with Gd-EOB-DTPA-enhanced MRI during HCC surveillance improved the clinical outcomes of patients with cirrhosis. We performed a retrospective cohort study of 421 HCC patients who were newly diagnosed during surveillance. Of these patients, 126 (29.9%) underwent surveillance based on Gd-EOB-DTPA-enhanced MRI and USG (USG+MRI group). The patients (295, 70.1%) who did not undergo MRI during surveillance were referred to as the USG group. In the USG+MRI group, 120 (95.2%) of 126 patients were diagnosed with early-stage HCC, whereas 247 (83.7%) of 295 patients were diagnosed with early-stage HCC in the USG group (P = 0.009). The significantly longer overall survival and time to progression in patients in the USG+MRI group compared to the unmatched cohort USG group was consistently observed by inverse probability weighting and propensity score-matched analysis. Gd-EOB-DTPA-enhanced MRI combined surveillance improved the detection of early-stage HCC and clinical outcomes such as overall survival and the time to progression in patients with cirrhosis.
format Online
Article
Text
id pubmed-9953123
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99531232023-02-25 Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis Yu, Su Jong Yoo, Jeong-Ju Lee, Dong Ho Kim, Su Jin Cho, Eun Ju Kim, Se Hyung Lee, Jeong-Hoon Kim, Yoon Jun Lee, Jeong Min Lee, Jae Young Yoon, Jung-Hwan Biomedicines Article Gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) can detect early stages of hepatocellular carcinoma (HCC). However, the survival benefit of Gd-EOB-DTPA-enhanced MRI in the surveillance of patients with cirrhosis has not yet been determined. We explored whether the intermittent replacement of ultrasonography (USG) with Gd-EOB-DTPA-enhanced MRI during HCC surveillance improved the clinical outcomes of patients with cirrhosis. We performed a retrospective cohort study of 421 HCC patients who were newly diagnosed during surveillance. Of these patients, 126 (29.9%) underwent surveillance based on Gd-EOB-DTPA-enhanced MRI and USG (USG+MRI group). The patients (295, 70.1%) who did not undergo MRI during surveillance were referred to as the USG group. In the USG+MRI group, 120 (95.2%) of 126 patients were diagnosed with early-stage HCC, whereas 247 (83.7%) of 295 patients were diagnosed with early-stage HCC in the USG group (P = 0.009). The significantly longer overall survival and time to progression in patients in the USG+MRI group compared to the unmatched cohort USG group was consistently observed by inverse probability weighting and propensity score-matched analysis. Gd-EOB-DTPA-enhanced MRI combined surveillance improved the detection of early-stage HCC and clinical outcomes such as overall survival and the time to progression in patients with cirrhosis. MDPI 2023-01-27 /pmc/articles/PMC9953123/ /pubmed/36830919 http://dx.doi.org/10.3390/biomedicines11020382 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yu, Su Jong
Yoo, Jeong-Ju
Lee, Dong Ho
Kim, Su Jin
Cho, Eun Ju
Kim, Se Hyung
Lee, Jeong-Hoon
Kim, Yoon Jun
Lee, Jeong Min
Lee, Jae Young
Yoon, Jung-Hwan
Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis
title Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis
title_full Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis
title_fullStr Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis
title_full_unstemmed Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis
title_short Adding MRI as a Surveillance Test for Hepatocellular Carcinoma in Patients with Liver Cirrhosis Can Improve Prognosis
title_sort adding mri as a surveillance test for hepatocellular carcinoma in patients with liver cirrhosis can improve prognosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953123/
https://www.ncbi.nlm.nih.gov/pubmed/36830919
http://dx.doi.org/10.3390/biomedicines11020382
work_keys_str_mv AT yusujong addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis
AT yoojeongju addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis
AT leedongho addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis
AT kimsujin addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis
AT choeunju addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis
AT kimsehyung addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis
AT leejeonghoon addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis
AT kimyoonjun addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis
AT leejeongmin addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis
AT leejaeyoung addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis
AT yoonjunghwan addingmriasasurveillancetestforhepatocellularcarcinomainpatientswithlivercirrhosiscanimproveprognosis